Browsing Tag
Zevra Therapeutics
3 posts
Zevra Therapeutics appoints new CFO. Is the rare disease biotech entering its next commercial cycle?
Zevra Therapeutics appoints Justin Renz as CFO as the rare disease biotech prepares for commercialization expansion. Read what the leadership move signals.
Zevra Therapeutics’ MIPLYFFA receives FDA approval as first treatment for Niemann-Pick disease
Zevra Therapeutics Inc. has announced U.S. Food and Drug Administration (FDA) approval of MIPLYFFA (arimoclomol), a capsule-based treatment…
FDA committee endorses Zevra Therapeutics’ arimoclomol as a treatment for Niemann-Pick Disease Type C
In a notable advancement for rare disease treatment, Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has received a significant endorsement…